ライフサイエンスコーパス: nonmalignant

1 n in malignant T24 bladder cells, but not in nonmalignant 293 or NIH 3T3 cells.

2 ulated in malignant cell lines compared with nonmalignant acini.

3 DIs (aIRR, 1.52; 95% CI, 1.25-1.86) than for nonmalignant ADIs (aIRR, 1.12; 95% CI, 1.01-1.25), compa

4 sed screening and bisulfite sequencing of 20 nonmalignant and 29 PC tissue specimens were used to ide

5 NA metabolism elicits different responses in nonmalignant and cancer cells and suggests that the abno

6 s to differentiate between antigen levels on nonmalignant and cancer cells.

7 menin may be important in the regulation of nonmalignant and CCA proliferation and may be an additio

8 egulated, and the molecular underpinnings of nonmalignant and malignant hematologic disorders.

9 successful treatment for many patients with nonmalignant and malignant liver diseases.

10 for somatic mutations in the pathogenesis of nonmalignant and/or autoimmune hematologic conditions in

11 enhanced MR imaging that subsequently proved nonmalignant at biopsy were retrospectively reviewed.

12 n humans is a major trigger of malignant and nonmalignant B cell proliferations.

13 ese results indicate that although silent in nonmalignant B cells, a defect in the INK4-Cdk4 checkpoi

14 biopsy specimens from patients with EAC and nonmalignant Barrett's esophagus (BE), with or without d

15 t distinguished patients with malignant from nonmalignant biopsies.

16 nantly phosphoproteins) in matched tumor and nonmalignant biopsy specimens from 23 patients with head

17 retreatment esophageal adenocarcinoma and 49 nonmalignant biopsy tissues from patients undergoing end

18 oglobinuria (PNH) are pathogenically related nonmalignant bone marrow failure disorders linked to T-c

19 r to multiple myeloma cells from neighboring nonmalignant bone marrow stromal cells.

20 l cells from either reduction mammoplasty or nonmalignant breast cell lines, we observed a unique cel

21 upregulated in malignant cells compared with nonmalignant breast cells.

22 d a three-dimensional culture model in which nonmalignant breast epithelial cells form spheroids remi

23 Nonmalignant breast epithelial cells show a similar visc

24 This receptor complex acutely sensitizes nonmalignant breast epithelial cells to activation by ty

25 1-integrin and NF-kappaB p65 were induced in nonmalignant breast epithelial cells, but not in maligna

26 at a higher reading level than were those on nonmalignant breast lesions (grade level readability sco

27 One hundred seventy-five nonmalignant breast lesions in 165 women were evaluated.

28 ernet search using three malignant and eight nonmalignant breast lesions that traditionally require l

29 ast tumors are stiffer and more hypoxic than nonmalignant breast tissue.

30 was higher in lung cancer cell lines than in nonmalignant bronchial epithelial cells.

31 encing analysis of the LL-like lymphomas and nonmalignant bursa tissues of the RFS line of birds iden

32 t has showed significant differences between nonmalignant cancer cells and the cancerous ones for bot

33 ant lesions was significantly higher than in nonmalignant cases (13.2 +/- 6.2 vs. 2.3 +/- 1.2, P = 0.

34 or the differentiation between malignant and nonmalignant cases.

35 city for tumor vasculature and the different nonmalignant causes that can impact CEC.

36 with malignant CBD stenoses than controls or nonmalignant CBD stenoses (2.41 x 10(15) vs 1.60 x 10(14

37 this threshold discriminated malignant from nonmalignant CBD stenoses with 100% accuracy.

38 hed patients with malignant vs patients with nonmalignant CBD stenoses with 63.3% diagnostic accuracy

39 Vs in bile could discriminate malignant from nonmalignant CBD stenoses.

40 riminates between patients with malignant vs nonmalignant CBD stenosis with 100% accuracy.

41 NOX2 inhibition had no detectable effect on nonmalignant CD34(+) cell survival.

42 Although mitochondrial transfer from BMSC to nonmalignant CD34(+) cells occurs in response to oxidati

43 ls have increased mitochondria compared with nonmalignant CD34(+) hematopoietic progenitor cells.

44 tions of malignant Sezary cells (SCs) versus nonmalignant CD4(+) T cells from 3 patients for whole tr

45 arger in cancerous bladder cells compared to nonmalignant cell cancer of the ureter (HCV29 cells).

46 mors when compared with normal tissues and a nonmalignant cell line and is correlated inversely with

47 Fibroblasts are the major nonmalignant cell type in the stroma of human pancreatic

48 CLCs) but have AMPK-activating properties in nonmalignant cell types, we set out to investigate this

49 toxic (up to 100 muM) toward representative nonmalignant cells (fibroblasts).

50 thelial tumors recruit fibroblasts and other nonmalignant cells and activate them into cancer-associa

51 However, such inhibitors may also affect nonmalignant cells and cause pronounced off-target effec

52 rsion of malignant cells into phenotypically nonmalignant cells in 3D gels, we identified FAM83A as a

53 that these mimetics enhance the survival of nonmalignant cells in a zebrafish model of metastasis.

54 alpha2,6-SA and lower levels of LacNAc than nonmalignant cells in culture and in vivo and that nucle

55 effects of radiation exposure, predominantly nonmalignant cells in the tumor microenvironment manifes

56 a functional interplay between malignant and nonmalignant cells in the tumor microenvironment.

57 we show that increasing oxidative stress in nonmalignant cells induced their sensitization to the ef

58 n engineered, functionally inducible MMP9 in nonmalignant cells led to loss of tissue polarity, and r

59 We propose that antigen expression in nonmalignant cells may contribute to the efficacy of T-c

60 ggested the hypothesis that APN expressed by nonmalignant cells might promote tumor growth.

61 he donor immune system against malignant and nonmalignant cells of the recipient.

62 The growth of nonmalignant cells or MYCN-nonamplified neuroblastoma ce

63 Diverse drugs targeting malignant and nonmalignant cells receive clinical approval each year f

64 selectively targets mitochondria, cancer and nonmalignant cells respond differently to disruption of

65 Overexpression of PIP5K1alpha in PNT1A nonmalignant cells results in an increased AKT activity

66 rs selective mRNA translation, reprogramming nonmalignant cells to an invasive phenotype by reducing

67 onducted a targeted chemical screen in human nonmalignant cells to validate known and search for nove

68 Targeting cancer cells and nonmalignant cells unavoidably changes the tumor microen

69 a differential behavior toward malignant and nonmalignant cells was observed for SeChry and SePQue, e

70 Perturbation of such boundaries in nonmalignant cells was sufficient to activate proto-onco

71 S analysis comparing conditioned medium from nonmalignant cells with or without active MMP9 revealed

72 d mitochondrial accumulation of FerT endowed nonmalignant cells with tumor-forming ability.

73 All nonmalignant cells within and surrounding the tumor are

74 -quadruplexes, their uptake in malignant and nonmalignant cells, and their capacity to modulate gene

75 In nonmalignant cells, AS was expressed at higher levels th

76 In nonmalignant cells, the V-ATPase inhibitor archazolid in

77 In contrast, these effects did not occur in nonmalignant cells.

78 heterogeneous malignant cells and associated nonmalignant cells.

79 pathogenic microorganisms in cancer, but not nonmalignant cells.

80 nabled T cells to distinguish malignant from nonmalignant cells.

81 lines, while remaining highly attenuated in nonmalignant cells.

82 pression levels differed in malignant versus nonmalignant cells.

83 induced the anchorage-independent growth of nonmalignant cells.

84 ttle is known about how dasatinib influences nonmalignant cells.

85 ake, whereas no stimulation was observed for nonmalignant cells.

86 CAP exposure did not result in apoptosis for nonmalignant cells.

87 required to detect the fusion transcript in nonmalignant cells.

88 to VSV, while remaining highly attenuated in nonmalignant cells.

89 or selective p53-dependent cytoprotection of nonmalignant cells.

90 compartmentalized pressure characteristic of nonmalignant cells.

91 cer, n = 20 or cholangiocarcinoma, n = 5) or nonmalignant (chronic pancreatitis [CP], n = 15) origin.

92 roxysmal nocturnal hemoglobinuria (PNH) is a nonmalignant clonal disease of hematopoietic stem cells

93 increased H2S production, compared with the nonmalignant colonic mucosa cells, NCM356.

94 oproliferative disorder (RALD) is a chronic, nonmalignant condition that presents with persistent mon

95 e importance and function of this pathway in nonmalignant conditions as well as malignancies (includi

96 ansplantation as a therapy for malignant and nonmalignant conditions is complicated by pulmonary infe

97 0), whereas second malignancies (n = 20) and nonmalignant conditions possibly associated with radioth

98 gress in the treatment of many malignant and nonmalignant conditions.

99 iral infections after HSCT for malignant and nonmalignant conditions.

100 organ transplant, and immune suppression for nonmalignant conditions.

101 or chemotherapy in HSPC transplantation for nonmalignant conditions.

102 asingly used to treat multiple malignant and nonmalignant conditions.

103 tigated in 93 tissue samples (39 CCAs and 54 nonmalignant controls) using quantitative methylation-sp

104 nvasive bladder cancer tissues compared with nonmalignant controls.

105 ate cancer (PC) tissue samples compared with nonmalignant controls; however, its prognostic potential

106 uman endometrial tumors and cells with their nonmalignant counterparts, we found that upregulation of

107 tic cancer or cholangiocarcinoma, n = 15) or nonmalignant (CP, n = 15) CBD stenosis.

108 cohort study of all patients (N = 671) with nonmalignant cytology who had thyroidectomy between Octo

109 erstandings about the trajectory of advanced nonmalignant disease among patients, families, and perha

110 he main risk factor for developing an AD was nonmalignant disease as an indication for CBT (P = .0001

111 iated with mortality from other malignant or nonmalignant disease, the authors examined the associati

112 iatric AlloHCT recipients with malignant and nonmalignant disease.

113 ar complications compared with children with nonmalignant disease.

114 ching in unrelated donor transplantation for nonmalignant diseases (NMD) has yet to be defined.

115 nts developing ADs were younger and had more nonmalignant diseases (P < .001).

116 ons in a variety of cancers and perhaps many nonmalignant diseases as well.

117 treatment of tumors and for the diagnosis of nonmalignant diseases associated with a remodeling of th

118 thesis also opened doors to treating various nonmalignant diseases characterized by abnormal vasculat

119 est study to date reporting on patients with nonmalignant diseases demonstrating HCT-CI scores >=3 th

120 ts relationship to malignancies, its link to nonmalignant diseases of aging, and its potential impact

121 o altered immune function, inflammation, and nonmalignant diseases of aging.

122 hematopoietic cell transplantation (HCT) for nonmalignant diseases remains a significant problem.

123 poietic stem cell transplantation (HSCT) for nonmalignant diseases result in increased risk for adver

124 Nonmalignant diseases such as bone marrow suppression an

125 h database, we identified 4083 patients with nonmalignant diseases transplanted between 2007 and 2014

126 The outcome in patients with nonmalignant diseases was acceptable, but transplant-rel

127 Nonmalignant diseases were associated with better 5-year

128 HSCs in the treatment of both malignant and nonmalignant diseases, as well as their use in gene ther

129 ngiogenic therapy outcomes for malignant and nonmalignant diseases.

130 vival after repeat liver transplantation for nonmalignant diseases.

131 the evaluation of HLA mismatches in HSCT for nonmalignant diseases.

132 tive treatment for a number of malignant and nonmalignant diseases.

133 e useful when developing treatment plans for nonmalignant diseases.

134 potential curative therapy for malignant and nonmalignant diseases.

135 T for hematologic malignancies (N = 4500) or nonmalignant disorders (N = 405) who received transplant

136 of new biologic treatments for malignant and nonmalignant disorders has enlarged the population at ri

137 ell transplantation (HSCT) for malignant and nonmalignant disorders is increasing, and late effects a

138 Twenty-three children with nonmalignant disorders received HLA-haploidentical hemat

139 ly curative treatment for both malignant and nonmalignant disorders, but when the body recognizes the

140 ts in the pathogenesis of both malignant and nonmalignant disorders, yet the factors affecting their

141 n is an effective approach for patients with nonmalignant disorders.

142 ells in 27 children with either malignant or nonmalignant disorders.

143 d for refractory hematologic cancer and some nonmalignant disorders.

144 allogeneic transplantation for children with nonmalignant disorders.

145 nd can now be applied to treat patients with nonmalignant disorders.

146 disparities and may be a useful strategy for nonmalignant disorders.

147 that are differentially activated in EAC vs nonmalignant dysplastic tissues; pathway activities were

148 ian 1-year survival compared with those with nonmalignant effusions (16.2% vs. 49.0%, respectively; l

149 ently in malignant T24 bladder cells than in nonmalignant embryonic kidney 293 or fibroblast NIH 3T3

150 (TEM) are antigens enriched in tumor versus nonmalignant endothelia.

151 rformed a microarray on tumor-associated and nonmalignant endothelium collected from patients with re

152 Benign prostatic hyperplasia (BPH), a nonmalignant enlargement of the prostate, is among the m

153 ed preferentially in cancer cells but not in nonmalignant epithelial cells.

154 plasmablasts were expanded, as compared with nonmalignant epithelium.

155 ed RNA sequencing of EC cell lines and their nonmalignant ES cell line counterparts.

156 control--that of a woman with suspicious but nonmalignant findings at MR imaging--was similarly match

157 calization of these FL-like cells (FLLCs) in nonmalignant GC-rich tissues and the functional conseque

158 on is a lifesaving therapy for malignant and nonmalignant hematologic diseases and metabolic disorder

159 ractive therapeutic option for patients with nonmalignant hematologic disorders and can mediate immun

160 HSCT has been a curative therapy for several nonmalignant hematologic disorders through the provision

161 Most nonmalignant hematological disorders require transfusion

162 For many nonmalignant hematological disorders, HLA-matched bone m

163 centives for new physicians to specialize in nonmalignant hematology.

164 logist positions that predominantly focus on nonmalignant hematology.

165 antly expressed in HepG2 cells compared with nonmalignant hepatocytes.

166 understand HSC-niche interactions in altered nonmalignant homeostasis, we selected beta-thalassemia,

167 ed that CD13 (aminopeptidase N) expressed by nonmalignant host cells of unspecified types regulate tu

168 iciency in allografted malignant (tumor) and nonmalignant (host) cells on tumor growth and metastasis

169 ion of glucose transporter type 3 (GLUT3) in nonmalignant human breast cells activated known oncogeni

170 In nonmalignant human cells, EGF stimulates robust activati

171 1, CCLP, HuCCT-1, and HuH-28, as well as the nonmalignant human intrahepatic biliary line, H69.

172 Initially, nonmalignant human mammary epithelial cells (MCF-10A) we

173 Inactivation of RORalpha in nonmalignant human mammary epithelial cells inhibited SE

174 results in the neoplastic transformation of nonmalignant human SV-HUC urothelial cells.

175 ry infection, one of whom developed a lethal nonmalignant illness.

176 ntribute to clinical responses by modulating nonmalignant immune cells.

177 s (122), hematologic malignancies (106), and nonmalignant immunosuppression (77).

178 Nonmalignant immunosuppression and hematologic malignanc

179 d into hematologic or solid malignancies and nonmalignant immunosuppression.

180 rs examined the potential for confounding by nonmalignant indications for surgery on breast cancer ri

181 trongly confounded by failure to account for nonmalignant indications for surgery.

182 aged 0-65 years undergoing tonsillectomy for nonmalignant indications were recruited in 6 hospitals i

183 aches are in development for solid-tumor and nonmalignant indications, broadening the scope of this t

184 tation is under investigation for a range of nonmalignant indications, including tolerance induction

185 with expected survival comparable to that of nonmalignant indications.

186 r VLA-4-positive mouse 5TGM1-GFP myeloma and nonmalignant inflammatory host cells such as T cells and

187 e served as an additional control to provide nonmalignant inflammatory lymphadenopathy.

188 ates), structures previously associated with nonmalignant intestinal pathology, nearly universally (8

189 All complexes were inactive against nonmalignant keratinocytes but displayed variable activi

190 r objective was to describe the incidence of nonmalignant late complications and their association wi

191 The cumulative incidence of any nonmalignant late effect at 5 years after HCT was 44.8%

192 The burden of nonmalignant late effects after HCT is high, even with m

193 h nodes exhibited the lowest mean ADC of all nonmalignant lesions ([1.28 +/- 0.23] x 10(-3) mm(2)/sec

194 l pancreatectomy (LDP) versus open (ODP) for nonmalignant lesions was modeled in a decision tree.

195 st DCE MRI examinations (54 malignant and 57 nonmalignant lesions).

196 fluorescence imaging for lymph node mapping, nonmalignant lesions, nonsurgical purposes, or image gui

197 ponded, of whom 157 (64.1%) underwent PD for nonmalignant lesions.

198 sorting MCF-7 human breast cancer cells from nonmalignant leukocytes, while preserving the integrity

199 Expression of AFP in nonmalignant liver can occur, particularly in a subset o

200 with HCC versus one of 31 (3%) patients with nonmalignant liver disease at risk for developing HCC (P

201 ology minimizing its toxicity to surrounding nonmalignant liver.

202 e to the burden of disease across a range of nonmalignant lung conditions in adults (in addition to t

203 bservation of reduced risks of malignant and nonmalignant lung diseases in the region.

204 We conducted a multiomics analysis of nonmalignant lung tissue to quantify the transcriptome,

205 h TANs and neutrophils isolated from distant nonmalignant lung tissue were able to stimulate T cell p

206 her rate than epithelial cells isolated from nonmalignant lung tissue.

207 e syndrome (ALPS) presents in childhood with nonmalignant lymphadenopathy and splenomegaly associated

208 hat often manifest in childhood with chronic nonmalignant lymphadenopathy, hepatosplenomegaly, and re

209 Ls also express elevated Gal-1 compared with nonmalignant lymphocytes, demonstrating the ability of t

210 syndrome (ALPS) is characterized by chronic nonmalignant lymphoproliferation, accumulation of double

211 Basal-like nonmalignant mammary epithelial cells also display an al

212 nhanced expression of antioxidant enzymes in nonmalignant mammary epithelial cells detached from ECM

213 TNBC cells, but not nonmalignant mammary epithelial cells, were dependent on

214 it had little effect on the survival of the nonmalignant MCF-10A breast epithelial cells.

215 Nonmalignant MCF-10A cells, however, were unaffected.

216 gnant (MCF-7 cells and MDA-MB-231 cells) and nonmalignant (MCF-10A cells) states.

217 d 196 SMNs, 419 nonmelanoma skin cancers, 21 nonmalignant meningiomas, and 43 other benign neoplasms.

218 urotaxis has been characterized primarily in nonmalignant mesenchymal cells, little is known about it

219 mouse model of Camurati-Engelmann disease, a nonmalignant metabolic bone disorder associated with inc

220 ession are due to genetic differences in the nonmalignant microenvironment.

221 We applied LQ-DGE to profile malignant and nonmalignant mouse and human cells, demonstrating its qu

222 expression and minimal inflammation seen in nonmalignant mucosa.

223 ments NK cell responses toward malignant and nonmalignant myeloid cells.

224 ment esophageal adenocarcinoma (N = 115) and nonmalignant (N = 183) biopsy tissues.

225 Desmoid tumors are nonmalignant neoplasms of mesenchymal origin that mainly

226 r and is characterized by both malignant and nonmalignant neurofibromas, which are composed of Schwan

227 ogenous leukemia, we show that malignant and nonmalignant neutrophils are more prone to NET formation

228 important step in melanoma progression from nonmalignant nevi with BRAF mutations.

229 Using the nonmalignant NF-kappaB-activated androgen-depleted mouse

230 rected mitochondrial accumulation of FerT in nonmalignant NIH3T3 cells increased their ETC complex I

231 ntly greater than admissions with underlying nonmalignant non-primary immunodeficiency hematologic di

232 mmon cause of Budd-Chiari syndrome (BCS) and nonmalignant, noncirrhotic portal vein thrombosis (PVT).

233 Data from the chronic nonmalignant pain literature suggest that toxicities may

234 ances, their use in the treatment of chronic nonmalignant pain remains controversial.

235 they are efficacious in treatment of chronic nonmalignant pain remains controversial.

236 ndations for the use of IDD for cancer pain, nonmalignant pain, and spasticity, as well as a new stud

237 As with chronic nonmalignant pain, multimodal interventions that incorpo

238 ment of cancer pain, spasticity, and chronic nonmalignant pain.

239 ications, including alcoholism, anxiety, and nonmalignant pain.

240 2010) was performed to find patients with a nonmalignant papillary breast lesion diagnosed at CNB.

241 nted with pancreatic cells isolated from the nonmalignant part of the surgical specimen (experimental

242 Extrahepatic nonmalignant partial PVT improved spontaneously in 45% o

243 s with cirrhosis and untreated extrahepatic, nonmalignant partial PVT were followed up until the fina

244 R 1.59, 95% CI 1.17-2.16), neuroendocrine or nonmalignant pathology (OR 1.56, 95% CI 1.18-2.06), conc

245 crease cytotoxicity of dexamethasone against nonmalignant peripheral blood lymphocytes, mesenchymal s

246 ell lines, and decreased upon reversion to a nonmalignant phenotype.

247 ntains extracellular matrix and a variety of nonmalignant populations, including myeloid cells, lymph

248 ies of biliary brush samples (15 CCAs and 20 nonmalignant primary sclerosing cholangitis controls), a

249 compared with those having an operation for nonmalignant processes (2.1% [128 of 6213] vs 2.3% [232

250 In this study, we silenced DLC1 in nonmalignant prostate epithelial cells to explore its tu

251 the TMPRSS2:ERG fusion in both malignant and nonmalignant prostate epithelial cells.

252 and prognostic potential was evaluated in 35 nonmalignant prostate tissue samples, 293 radical prosta

253 with PVT, 60 were extracted who had chronic, nonmalignant PVT, after exclusion of those with sclerosi

254 We have previously demonstrated in nonmalignant rat intestinal IEC-6 cells that schlafen 3

255 ponse trends occurred for both malignant and nonmalignant renal disease (12 and 13 deaths, respective

256 e exposure-response trends for malignant and nonmalignant renal disease.

257 lly attained FEV(1) had an increased risk of nonmalignant respiratory disease mortality (using invers

258 norganic arsenic and ischemic heart disease, nonmalignant respiratory disease, and lung, skin, bladde

259 COPD and 215 deaths, of which 55 were due to nonmalignant respiratory disease.

260 onal contribution to the burden of the major nonmalignant respiratory diseases, including airway dise

261 on of occupational factors across a range of nonmalignant respiratory diseases.

262 However, the effects on nonmalignant respiratory mortality are less studied, and

263 p of long-term exposure to air pollution and nonmalignant respiratory mortality in 16 cohorts with in

264 ociations between air pollution exposure and nonmalignant respiratory mortality.

265 sociation between air pollution exposure and nonmalignant respiratory mortality.

266 The 5-y survival rates in nonmalignant SBS-IF patients who initiated HPS were 89.1

267 ome data from a well-characterized cohort of nonmalignant short bowel syndrome (SBS) patients.

268 h factor (NGF) attenuates both malignant and nonmalignant skeletal pain.

269 V DNA in both malignant (CTCL, melanoma) and nonmalignant skin and sentinel lymph nodes but not in hi

270 melanoma and tumor suppressor activities in nonmalignant skin cancer.

271 d developmental and neurological disease and nonmalignant skin photosensitivity.

272 at we can discriminate between malignant and nonmalignant stroma spectra with high sensitivity (93.56

273 ived specifically from either tumor cells or nonmalignant stromal cells that predict patient outcome

274 n in APN expression by both cancer cells and nonmalignant stromal cells within the tumor microenviron

275 mprises a complex mixture of tumor cells and nonmalignant stromal cells, including neurons, astrocyte

276 at are surrounded by a diverse complement of nonmalignant stromal cells.

277 ions requiring additional work-up from other nonmalignant subtypes may further improve patient care.

278 ated KRAS gene can also be associated with a nonmalignant syndrome of autoimmunity and breakdown of l

279 umab infusions directed predominantly toward nonmalignant T cells rosetting around Reed-Sternberg cel

280 on in malignant T cells when cocultured with nonmalignant T cells, indicating an indirect mode of act

281 expression in cocultures with SEA-responsive nonmalignant T cells.

282 ed and primary patient-derived malignant and nonmalignant T cells.

283 evels in tumors relative to matched adjacent nonmalignant tissue from the same patient among 736 miRN

284 re-existing blood vessels of the surrounding nonmalignant tissue.

285 with altered methylation in tumoral but not nonmalignant tissue.

286 ences between MR parameters in malignant and nonmalignant tissue.

287 ignificantly different between malignant and nonmalignant tissue.

288 s highly variable background expression from nonmalignant tissues and tumor heterogeneity.

289 However, malignant and nonmalignant tissues are usually distinguished on fluore

290 CD133(-)) cells isolated from malignant and nonmalignant tissues of clinically characterized human b

291 Because the uptake of CRL-3-(99m)Tc by nonmalignant tissues was negligible and retention in the

292 fferentiating malignant tissues from certain nonmalignant tissues with high glucose uptake.

293 ived from the tumor microenvironment or from nonmalignant tissues, have the capacity to reciprocally

294 was upregulated significantly compared with nonmalignant tissues.

295 xhausted T cells within tumors while sparing nonmalignant tissues.

296 proteins in EAC tumor tissues compared with nonmalignant tissues.

297 ors, those with a history of a benign tumor (nonmalignant tumor with functional impairment), and thos

298 PD-L1 is also expressed by nonmalignant tumor-associated macrophages (TAMs), but th

299 paB:AP-1 pro-oncogenic signaling pathways in nonmalignant versus malignant T and B lymphocytes.

300 -guanosine triphosphate activity, similar to nonmalignant, young HSC/Ps.